GLP-1 Resource Center

Does Ozempic affect bone density?

Bone density during GLP-1 treatment is an emerging area of research and is rarely discussed at the point of prescribing. Rapid weight loss of any kind is associated with reduced bone mineral density, and GLP-1 medications produce weight loss quickly.

The evidence

Some analyses of GLP-1 medication trials have reported modest reductions in bone mineral density markers in certain patient groups during treatment. The concern is not specific to GLP-1 medications. It follows from rapid weight loss itself. Research reports that bone mineral density may decrease during active caloric restriction. In STEP 1 (Wilding et al., NEJM 2021), semaglutide at 2.4mg weekly produced average weight loss of 14.9 percent over 68 weeks; in SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide at 15mg weekly produced an average of 22.5 percent. Losses of that size compressed into a short timeframe are the reason the question is being asked.

Why lower nutrient intake is part of the discussion

Calcium and vitamin D are the primary nutritional inputs for bone mineral density maintenance.* A 2025 joint advisory from four professional societies (Mozaffarian et al., Obesity) reported caloric intake reductions of 16 to 39 percent across the GLP-1 drug class, meaning calcium and vitamin D intake may fall alongside it. On current standardised national data, around 5 percent of American adults are at risk of vitamin D deficiency and a further 18 percent fall short of adequacy, so reduced food intake may compound an already common shortfall. Lower magnesium intake, common when eating less, is also discussed as affecting how the body uses calcium.

Who the research focuses on

Women over 40 receive the most attention in this literature. Women lose approximately 1 percent of bone density per year after age 40, rising to 2 to 3 percent per year during menopause. Rapid weight loss on top of that trajectory is worth raising with a clinician. If you are over 40 and losing significant weight on a GLP-1 medication, ask your provider whether a DEXA scan is appropriate for you. That measurement, rather than a symptom list, is what tells you where you stand.

What the evidence supports

Adequate calcium intake, vitamin D, magnesium and weight-bearing activity are what the evidence points to during periods of rapid weight loss. Weight-bearing activity has the most evidence behind it; studies suggest it may help support bone density during caloric restriction.*

It is worth naming what does not help, because creatine is often suggested in this context. A June 2026 meta-analysis in JISSN pooled seven randomised trials across 608 postmenopausal women and found lean mass higher by 0.37kg and leg press strength by 7.5kg, at 5g or more daily combined with resistance movement. Bone mineral density was unchanged across those trials. TAKE makes no bone claim for creatine or for TAKE Build.

Where TAKE fits, and where it does not

TAKE Complete includes vitamin D at 10mcg (50% DV) and zinc at 15mg (136% DV) per two-capsule serving, alongside its other vitamins and minerals.* Those are contributions toward daily intake rather than therapeutic doses. TAKE Complete contains saw palmetto and is not suitable in pregnancy, when nursing, or when trying to conceive. TAKE Hydrate contributes sodium 100mg, potassium 200mg, calcium 40mg and magnesium 20mg per 5.4g scoop as part of daily electrolyte intake.*

We would rather say this plainly than sell you something on it. If bone density is your specific concern, a multivitamin is not the intervention with the most evidence behind it. Weight-bearing activity is, and dedicated calcium and vitamin D at doses your provider decides on comes next. Ask them whether you need more than a multivitamin provides, and read what we do not claim for where our evidence stops generally.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always speak with your healthcare provider about medication side effects or medical concerns.